Skip to content

Prognostic utility of the NEOS score in pediatric antibody-negative encephalitis: A cohort study.

Aug 2026 · European journal of paediatric neurology · Vol 64, pp. 65-72 · 0 citations · 27 references
Medicine

TL;DR

The results suggest that the NEOS score could be a useful prognostic tool for identifying poor outcomes in children with antibody-negative AE, but may lack discriminatory value in anti-NMDAR cases.

Abstract

Background

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis and antibody-negative autoimmune encephalitis (AE) are important contributors to pediatric neurological morbidities; however, long-term outcomes and prognostic scores in these entities remain poorly defined, particularly in resource-limited areas.

Objective

To evaluate the predictive value of prognosis of the anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score in children with antibody-negative and anti-NMDAR AE in Vietnam.

Methods

We performed a retrospective and prospective cohort study of children with AE, evaluated at Children's Hospital 2 (CH2), Vietnam between January 2019 and June 2022, with follow-up completed in August 2023. Outcomes were evaluated at discharge and at final follow-up by the modified Rankin Scale (mRS). The NEOS score, estimated at initial hospitalization, was used to predict poor outcomes (mRS ≥ 2).

Results

This study included 82 pediatric patients with AE (<16 years old, 40 with anti-NMDAR encephalitis and 42 with antibody-negative AE), with median ages of 6.7 years (IQR: 4.2-12.2) and 7.4 years (IQR: 4.6-9.6), respectively. NEOS scores and complete outcome data were available for 78 patients (39 per group). At final follow-up, 79.5% of anti-NMDAR patients and 75.0% of antibody-negative AE patients achieved good functional outcomes (mRS 0-1), showing no significant between-group difference (p = 0.634). In antibody-negative AE, the NEOS score demonstrated predictive value for poor outcomes (mRS ≥ 2) with an AUC of 0.785 (p = 0.010), achieving 90% specificity and 55.6% sensitivity at a cut-off > 2, while showing no predictive ability in anti-NMDAR encephalitis (AUC = 0.520, p = 0.862). Both patient groups showed significant functional improvement, with median mRS scores decreasing from 2.0 (IQR: 1-4) at discharge to 0.0 (IQR: 0-1) at follow-up (p < 0.001). Follow-up assessments were conducted at a median of 19.5 months (IQR: 13.9-26.1) for anti-NMDAR patients and 23.7 months (IQR: 18.5-28.2) for antibody-negative AE patients.

Conclusions

Our results suggest that the NEOS score could be a useful prognostic tool for identifying poor outcomes in children with antibody-negative AE, but may lack discriminatory value in anti-NMDAR cases. Further multicenter prospective studies are needed to validate these findings and optimize prognostic tools for pediatric autoimmune encephalitis.

View source

Similar papers

Open access Oct 2026

Predictive value of persistent cerebrospinal fluid antibodies at 12 months for long-term clinical outcomes in pediatric anti-NMDAR encephalitis: a retrospective cohort study

Background and objective Persistent cerebrospinal fluid (CSF) antibodies against the N-methyl-D-aspartate receptor (NMDAR) are common in children recovering from anti-NMDAR encephalitis, but their association with long-term clinical outcomes remains unclear. This study aimed to assess whether persistent CSF NMDAR antib...

Hua Yang, Ru-Ling Zhang, Jie Yang et al. · 0 citations
Open access Sep 2026

Utility of the APE2 Score as a Diagnostic Tool for Autoimmune Encephalitis

ABSTRACT Objective To retrospectively evaluate the diagnostic performance of the Antibody Prevalence in Epilepsy and Encephalopathy (APE2) score relative to clinician‐adjudicated autoimmune encephalitis (AE) and the Graus criteria in a tertiary neuroimmunology referral cohort, including antibody‐negative AE. Methods We...

Bijoya Basu, Sophia F. Damman, Samhitha M. Rai et al. · 0 citations
Open access Aug 2026

Long-Term Outcomes in Autoimmune Encephalitis

Long-term cognitive impairment and fatigue were prevalent in AE, despite good functional outcomes as measured by the mRS, and the MoCA correlated well with neuropsychological performance and could be the bedside test of choice if a neuropsychologist is not readily available.

T. Gaist, Lisbeth Rosenlund Lodahl, Henrik Akre Thorup et al. · 0 citations
Review Open access Sep 2026

Daratumumab Treatment in Severe Anti-NMDAR Encephalitis

Objectives To describe clinical outcomes following daratumumab therapy in severe anti–N-methyl-d-aspartate receptor (NMDAR) encephalitis, including a literature review. Methods We report 2 patients with severe anti-NMDAR encephalitis treated with anti-CD38 daratumumab after failure of multiple immunotherapies. Clinical...

Nady Ammar, Marjolaine Uginet, P. De Stefano et al. · 0 citations
Open access Aug 2026

Relapse predictors and brain atrophy in antibody-positive and antibody-negative autoimmune encephalitis: a multicenter cohort study

Background Autoimmune encephalitis (AE) is clinically heterogeneous, but whether relapse predictors and structural correlates of disability differ by antibody status remains unclear. We aimed to identify serostatus-specific predictors of relapse and determine whether brain atrophy is associated with 12-month functional...

Xiaolong Tang, Jing-Xian Wang, Hao Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.